Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

CHHip: Conventional versus hypofractionated high-dose intensity modulated radiotherapy for localised prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.02.20
Views: 240

Prof David Dearnaley - Institute of Cancer Research, London, UK

Prof David Dearnaley speaks to ecancer at the 2020 ASCO GU meeting in San Francisco about the results from the CHHiP trial.

He outlines the background of this study, which aims to investigate the use of conventional versus hypofractionated high-dose intensity modulated radiotherapy for patients with localised prostate cancer.

Prof Dearnaley explains the results achieved from this eight-year follow up, which found that 60Gy/20f is non-inferior to 74Gy/37f.


Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation